Levonorgestrel intrauterine contraceptive systems (13.5 mg and 52 mg) and risk of ectopic pregnancy

被引:7
|
作者
Graner, Sofie [1 ,2 ]
Mc Taggart, Julia [3 ]
Nordstrom, Fanny [3 ]
Melander, Emma [3 ]
Widenberg, Johan [4 ]
Kallner, Helena Kopp [3 ,4 ,5 ]
机构
[1] Karolinska Inst, Karolinska Univ Hosp, Dept Med, Ctr Pharmacoepidemiol, Stockholm, Sweden
[2] Danderyd Hosp, Matern BB Stockholm, Stockholm, Sweden
[3] Karolinska Inst, Danderyd Hosp, Dept Clin Sci, Stockholm, Sweden
[4] Danderyd Hosp, Dept Obstet & Gynecol, Stockholm, Sweden
[5] Karolinska Inst, Dept Womens & Childrens Hlth, Stockholm, Sweden
关键词
Ectopic pregnancy; intrauterine contraception; levonorgestrel containing intrauterine system; levonorgestrel containing intrauterine system 13; 5; mg; levonorgestrel containing intrauterine system 52 mg; Pearl index; LNG-IUS; 8; PHASE-III; SINGLE-ARM; MULTICENTER; PROGESTASERT; SAFETY;
D O I
10.1111/aogs.13564
中图分类号
R71 [妇产科学];
学科分类号
100211 ;
摘要
Introduction The objective was to investigate the Pearl index for ectopic pregnancy in women using the levonorgestrel intrauterine system (LNG-IUS) at the time of conception. Material and methods This was a substudy of a hospital-based historical cohort including women with an ectopic pregnancy diagnosed in 4 referral hospitals in Stockholm, Sweden between December 2013 and April 2017. Study participants and type of contraception at time of conception were identified through the electronic medical chart system. Cases were defined as women with LNG-IUS 13.5 or 52 mg in situ at the time of diagnosis of ectopic pregnancy who had their LNG-IUS inserted 1 January 2014 or later. Outcome was defined as the incidence rate for ectopic pregnancy during use per 100 woman-years (Pearl index) with 95% confidence interval (95% CI). Results The study includes 35 cases with LNG-IUS 13.5 mg and 13 cases with LNG-IUS 52 mg, which occurred in 18 488 (13.5 mg) and 50 246 (52 mg) exposed woman-years. Pearl index for ectopic pregnancy was estimated at 0.19 (95% CI 0.15-0.28) for LNG-IUS 13.5 mg and to 0.006 (95% CI 0.00-0.01) for LNG-IUS 52 mg. The most cases for the LNG-IUS 13.5 mg (n = 26; 74%) occurred during the first year of use with a corresponding Pearl index at 0.23 (95% CI 0.14-0.35). Conclusions The absolute risk of ectopic pregnancy during the use of LNG-IUS remains low. Our method may underestimate as well as overestimate the Pearl index for ectopic pregnancy. The findings underline the importance of identifying risk factors for ectopic pregnancy at insertion, and to rule out ectopic pregnancy for all women presenting with abdominal discomfort during the use of LNG-IUS. Longer observation periods and prospective studies in a general population are a priority for further research.
引用
收藏
页码:937 / 943
页数:7
相关论文
共 50 条
  • [31] Five-year Contraceptive Use of 52-mg Levonorgestrel Releasing Intrauterine System in Young Women, Menstrual Patterns, and New Contraceptive Choice
    de Oliveira, Elaine Cristina Fontes
    Rocha, Ana Luiza Lunardi
    REVISTA BRASILEIRA DE GINECOLOGIA E OBSTETRICIA, 2023, 45 (11): : 654 - 660
  • [32] A case series on the use of levonorgestrel 52 mg intrauterine system after OF organ transplant
    Juliato, Cassia R. T.
    Stahlschmidt, Paulo
    Fernandes, Arlete
    Monteiro, Ilza
    Bahamondes, Luis
    CONTRACEPTION, 2018, 98 (03) : 252 - 254
  • [33] Levonorgestrel 52 mg intrauterine device placement without uterine sounding: A feasibility study
    Brown, Jewel A.
    Yazdani, Sheeva
    Economou, Nicole
    Rankin, Holly A.
    Flynn, Anne N.
    Creinin, Mitchell D.
    CONTRACEPTION, 2025, 142
  • [34] Expulsion and continuation rates of the 52 mg levonorgestrel intrauterine system in adolescents and adult women
    Brull, Eliza
    Machado, Helymar C.
    Bahamondes, Luis
    Juliato, Cassia R. T.
    EUROPEAN JOURNAL OF CONTRACEPTION AND REPRODUCTIVE HEALTH CARE, 2023, 28 (04): : 210 - 215
  • [36] Levonorgestrel 52 mg intrauterine system (Levosert®)/Liletta®) in contraception: a profile of its use
    Katherine A. Lyseng-Williamson
    Drugs & Therapy Perspectives, 2020, 36 : 539 - 546
  • [37] Steroid reservoir loss during removal of perforated Levonorgestrel 52 mg intrauterine device
    Dong, Allan C.
    Bush, Amanda J.
    CONTRACEPTION, 2019, 99 (03) : 192 - 193
  • [38] Levonorgestrel 52 mg intrauterine system efficacy and safety through 8 years of use
    Creinin, Mitchell D.
    Schreiber, Courtney A.
    Turok, David K.
    Cwiak, Carrie
    Chen, Beatrice A.
    Olariu, Andrea, I
    AMERICAN JOURNAL OF OBSTETRICS AND GYNECOLOGY, 2022, 227 (06)
  • [39] Contraceptive efficacy and safety of the 52-mg levonorgestrel intrauterine system for up to 8 years: findings from the Mirena Extension Trial
    Jensen, Jeffrey T.
    Lukkari-Lax, Eeva
    Schulze, Andrea
    Wahdan, Yesmean
    Serrani, Marco
    Kroll, Robin
    AMERICAN JOURNAL OF OBSTETRICS AND GYNECOLOGY, 2022, 227 (06) : 873.e1 - 873.e12
  • [40] Contraceptive efficacy and global licensing of 52 mg levonorgestrel intrauterine devices: does a Mirena last longer in New York than York?
    Nash, Zachary
    Thwaites, Annette
    BMJ SEXUAL & REPRODUCTIVE HEALTH, 2024, 50 (01) : 4 - 6